A cell-based Rb(+)-flux assay of the Kv1.3 potassium channel

Area of Science:

• Biochemistry
• Pharmacology
• Immunology

Background:

• Kv1.3 channels in human T lymphocytes are key therapeutic targets.
• Existing Kv1.3 inhibitors (e.g., scorpion venom peptides) are unsuitable for drug development.
• A reliable high-throughput screening (HTS) technology is crucial for discovering new Kv1.3 blockers.

Purpose of the Study:

• To develop and validate a cell-based HTS assay for identifying Kv1.3 channel inhibitors.
• To facilitate the screening of numerous potential drug candidates efficiently.
• To overcome the limitations of current screening methods for Kv1.3 channel modulators.

Main Methods:

• Developed a 96-well cell-based HTS assay using rubidium ion as a potassium ion tracer.
• Utilized atomic absorption spectroscopy for analyzing rubidium ion efflux.
• Validated assay performance using known Kv1.3 inhibitors (agitoxin, margatoxin) and other small molecules.

Main Results:

• The assay demonstrated excellent performance with a Z' factor of 0.813 and a 4.5-fold detection window.
• Agitoxin and margatoxin showed IC(50) values of 1.52 nM and 2 nM, respectively.
• Several non-peptide compounds, including tamoxifen, nifedipine, and fluoxetine, inhibited Kv1.3 channels, while astemizole and pimozide did not.

Conclusions:

• The developed HTS assay is a robust and reliable tool for discovering novel Kv1.3 channel inhibitors.
• The assay facilitates the identification of potential drug candidates for targeting Kv1.3 channels in T lymphocytes.
• This technology addresses a critical need in pharmaceutical research for developing new therapeutics based on Kv1.3 channel modulation.